Virginia Oncology Associates

🎙 NEW PODCAST EPISODE 🎙 Dr. Michael Miller, a radiation oncologist at Virginia Oncology Associates, discusses the incredible advancements in radiation oncology, especially the game-changing TrueBeam Varian linear accelerator, and how these innovations are enhancing treatment precision and patient outcomes. Through Dr. Miller's insights, you'll learn how radiation oncology uses high-precision x-rays to treat tumors with unparalleled accuracy. 🎧 Don't forget to like and share with others! You can find us on Apple Podcast, Spotify, Amazon Music, or anywhere podcasts are available. https://lnkd.in/eZTtdJqu #cancercareconnections #voa

Kevin K. Patel, MD was interviewed for HR Physician Magazine on the topic of advances in perioperative systemic treatment for resectable non-small cell lung cancer. Click to read more about the treatments available with promising outcomes for lung cancer patients. https://lnkd.in/eE8jJdyN Digital page 14 [copy page 26]

In the summer issue of HR Physician Magazine, Thomas A. Alberico, MD was recognized for his longtime legacy within the medical community in Hampton Roads. Dr. Alberico has been practicing medicine in Hampton Roads for almost 40 years and has been with Virginia Oncology Associates since 1986. “During that time, Dr. Alberico helped VOA grow from three physicians to 46 [now 51 since the publication of this article] subspecialists in facilities across the region to help eliminate or better manage disease…” Read more about Dr. Alberico’s impact on the Hampton Roads community. He is featured on digital page 5 [or copy pages 8-9] https://lnkd.in/eE8jJdyN

PLEASE JOIN US live and in person for our 6th Annual VOA Nursing Conference on September 28, 2024 at Hilton Norfolk - The Main. The conference will be held from 7:00 AM - 3:00 PM. Virginia Oncology Associates is committed to providing and promoting healthcare education activities throughout our community and beyond. Participants meeting successful completion criteria will be awarded 5 NCPD contact hours. Click here to register https://lnkd.in/eeHFSsj3 The registration fee is $35.

We welcome John Xie, MD, to Virginia Oncology Associates. Dr. Xie joins our team of medical oncologists and hematologists, and is taking patients at our Harbour View and Obici locations. Click here to learn more about Dr. Xie. https://lnkd.in/eQ9Vifpj

We welcome Chike O. Abana, MD, PhD, to Virginia Oncology Associates. Dr. Abana joins our team of radiation oncologists. He is taking patients at our Hampton and Norfolk locations.

September is Prostate Cancer Awareness Month and we are proud to announce that Mark Fleming, MD has been recognized by Newsweek as one of "America's Best Prostate Cancer Oncologists" in 2024. As a co-founding member and Past-President of the Hampton Roads Prostate Health Forum, Dr. Fleming is a passionate speaker on the importance of cancer education and the Early Detection of Prostate Cancer. To learn more about Dr. Fleming, visit https://lnkd.in/eJ8TVbkc https://lnkd.in/dNfKDzrn

We are excited to announce that VOA's Cathern "Katie" Cooke, CPhT is participating in the Healthcare Advocate Summit: "Voice of the Customer." She is speaking at Oncology: Unveiling the Complexities: Expert Insights into Oncology Access Programs and Reimbursement. 👏 There's still time to join!!!

Virginia Oncology Associates and Horizon CME would like to present "Evenings in Oncology: A Virtual Dinner Program" on Wednesday, August 28, 2024, from 5:55 - 7:50 pm (EST). This program will focus on managing infectious complications in immunocompromised cancer patients. Join Us! https://lnkd.in/eYbqaxxz

Dr. Michael Danso, an oncologist with a special interest in breast cancer at Virginia Oncology Associates, participated in a Breast Cancer Research roundtable with Touch, The Black Breast Cancer Alliance. They discussed how the death rate in black women is 40%+ higher than in white women and emphasized the need for more black women to be enrolled in clinical trials. Listen as Dr. Danso dives into the Victoria-1 clinical trial, a phase 3, open-label study evaluating Gedatolisib in combination with Palbociclib and Fulvestrant to SOC therapies in patients with HR+/HER2- metastatic breast cancer previously treated with CDK 4/6i and non-steroidal AI. Gedatolisib is an intravenous dual PI3K/mTOR inhibitor that has shown remarkable response rates in early phase trials. This trial is offered here at Virginia Oncology Associates. https://lnkd.in/g-JmskqR